A PHASE II STUDY OF DEPSIPEPTIDE IN PTS W/ RELAPSED/REFRACTORY MULTI MYELOMA

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究的目的是测试Depsipeptide作为复发性/缓解性多发性骨髓瘤患者治疗的安全性和有效性。如果患者同意，我们还将测试患者的骨髓样本，以测试哪些基因（如果有的话）会受到缩肽的影响。将在第1、8和15天通过外周IV或中心线以13 mg/m2在4小时内给予缩肽。每28天重复一个周期，直至疾病进展、患者出现不可耐受的副作用或撤回知情同意。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to test the safety and effectiveness of Depsipeptide as a treatment for patients with relapsed/refratory mutliple myeloma. If patients agree, we will also be testing samples of patients' bone marrow to test which genes, if any, will be affected by depsipeptide. Depsipeptide will be administered at 13mg/m2 over 4 hours on days 1, 8, and 15 through a peripheral IV or central line. Cycles will be repeated every 28 days until disease progression, patient experiences intolerable side effects, or withdraws consent.